Sanctuary Advisors LLC Invests $983,000 in Fresenius Medical Care AG (NYSE:FMS)

Sanctuary Advisors LLC acquired a new stake in shares of Fresenius Medical Care AG (NYSE:FMS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 39,434 shares of the company's stock, valued at approximately $983,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. ABC Arbitrage SA purchased a new position in shares of Fresenius Medical Care in the fourth quarter valued at about $4,215,000. Autumn Glory Partners LLC purchased a new position in Fresenius Medical Care in the fourth quarter worth about $208,000. Yousif Capital Management LLC bought a new position in shares of Fresenius Medical Care during the 4th quarter valued at approximately $208,000. DAVENPORT & Co LLC increased its position in Fresenius Medical Care by 1.5% during the fourth quarter. DAVENPORT & Co LLC now owns 58,147 shares of the company's stock valued at $1,316,000 after acquiring an additional 862 shares during the last quarter. Finally, Blue Trust Inc. raised its position in Fresenius Medical Care by 15.6% in the 4th quarter. Blue Trust Inc. now owns 14,876 shares of the company's stock worth $317,000 after purchasing an additional 2,013 shares during the period. Hedge funds and other institutional investors own 8.37% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Bank of America raised shares of Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a research report on Monday, December 2nd. Truist Financial boosted their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a "hold" rating in a report on Monday, January 6th. StockNews.com raised Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Finally, Berenberg Bank started coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They set a "buy" rating and a $25.60 price target on the stock.

Remove Ads

Fresenius Medical Care Stock Performance

NYSE FMS traded up $0.41 on Friday, reaching $24.21. 395,091 shares of the company's stock traded hands, compared to its average volume of 255,900. Fresenius Medical Care AG has a fifty-two week low of $17.93 and a fifty-two week high of $25.25. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The firm has a market cap of $14.20 billion, a price-to-earnings ratio of 20.00, a P/E/G ratio of 0.76 and a beta of 0.93. The stock has a 50 day moving average price of $23.45 and a 200-day moving average price of $21.86.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.